Combination therapy using ribociclib and fulvestrant for the treatment of HR+ breast cancer
AssigneeNovartis AG
InventorsYan Chen, Xizhong Huang, Sunkyu Kim
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.
Claims10
A method of treating HR+ breast cancer in a human, comprising administering to the human therapeutically effective levels of Compound A1, or a pharmaceutically acceptable salt thereof:
- and therapeutically effective levels of fulvestrant.
A method of administering Compound A1, or a pharmaceutically acceptable salt thereof:
- and fulvestrant to a human HR+ breast cancer patient, the method comprising administering Compound A1 and fulvestrant to the patient to provide therapeutically effective levels of Compound A1 and fulvestrant in the patient.
Dependencies are inferred from the claim text.